Startup City: Presented By Mayo Clinic & Destination Medical Center

Showcase your innovation to the DxPx audience & network with investors and strategics right on the floor of ADLM 2024.

Package price: $3,500

Showcase your startup and offer a meeting hub for investors right in the heart of ADLM 2024
Limited booth spaces are available, ensuring a high level of visibility for each Startup City participant
Includes 1 free Startup DxPx registration valued at $999 with access to 1x1 partnering, DxPx panels, and networking
Your company will also be listed on the main ADLM 2024 floorplan and is accessible by all ADLM visitors

Startup City Booth Benefits

A Meeting hub at DxPx U.S.

In addition to our on-site, one-to-one meeting rooms, your booth is a personal hub to meet with investors and partners.

Enhance visibility among investors

Showcase your company’s USPs and investment opportunities on the floor of ADLM 2024 in DxPx Startup City.

Supplement One-on-One Partnering

Missed connecting with one of your target partners in our digital partnering app? Use your booth as an additional meeting point in between the pre-scheduled one-on-ones.

Maximize your time at DxPx

Our team handles all booth setup and teardown so that you can fully focus making new connections and making the most of DxPx U.S. 2024.

Booths = Maximum Value at DxPx

One registration ($999 value) is included with each booth purchase. Add another registration at 50% off when you apply for the 42PLUS1 Pitch Competition.

Limited Space - Apply Now!

We only grant booth to sponsors and innovative startups. Spaces are therefore limited to insure that every exhibitor gains the desired exposure.

DxPx U.S. 2024 Exhibitors Include:

Ad Astra Diagnostics, Inc. (AAD) is developing the fastest need-to-result complete blood count in a rugged, easy-to-use, patient-side system designed to go anywhere. AAD’s QScoutTM RLD is the only FDA cleared test to quantitate at point of care immature granulocytes, a sepsis marker. AAD develops rapid diagnostic and data systems that enable fast point of care health decisions to support its vision of making diagnostics more accessible.

For more information, visit: https://www.adastradx.com/

BACTEROMIC develops the most informative Antibiotic Susceptibility Testing system designed to assess antimicrobial resistance against even all clinically-relevant antibiotics in a single test. The highly versatile system is set to provide the most precise information about the optimal treatment and MIC level with an ultimate goal of results under 6-8h. Currently, BACTEROMIC has a first UNI25 Panel certified in the EU and develops new product – Positive Blood Culture Panel addressing bloodstream infections.

For more information, visit: https://bacteromic.com/

Elyte has developed an innovative point-of-care testing (POCT) device, designed specifically for individuals at risk of potassium imbalances due to cardiac or renal conditions. Its cutting-edge technology enables patients to accurately measure and monitor their potassium levels in the comfort of their own homes, a significant advancement from traditional methods that rely on scheduled clinical visits and specialized laboratory equipment.

For more information, visit: elytediagnostics.com

Enzyre was founded with the mission to develop innovative diagnostic solutions to enable personalized medicine. The company holds the vision to create a point of care (POC) diagnostic platform that will measure a multitude of enzymatic reactions based on chemiluminescence.

For more information, visit: https://enzyre.com/

Genomtec is an innovative technology company developing a unique mobile point of care genetic testing platform for the clinical diagnostics market. The company has platform technology that can enable Point of Care Infectious Diseases diagnostics and companion diagnostics for Oncology. Its microfluidic lab-on-chip platform uses a patented non-contact heating and detection system and a proprietary LAMP based isothermal amplification methods. The company’s first asset is a multiplexed molecular diagnostics assay that can rapidly identify Influenza A/B, RSV A/B, SARS-CoV-2 and M.pneumoniae pathogens. Genomtec is currently working on EGFR markers in non-small cell Lung Cancer. The company is looking for strategic partnership opportunities for CDx menu development, M&A, and OEM licensing.

For more information, visit: www.genomtec.com

NADMED is a developer of NAD measuring technology designed for extracting and measuring nicotinamide adenine dinucleotides and glutathiones. The company’s technology is based on the novel nondestructive extraction of metabolites and colourimetric quantification and has been used to study research samples of cells, liver, brain, muscle, and blood of human or animal origin.

For more information, visit: www.nadmed.com

NeoPredix creates intelligent digital health solutions that facilitate decision making in clinical practice. Our goal is to improve the lives of children and their families, avoid unnecessary hospital stays, and reduce health care costs.

For more information, visit: https://neopredix.com/us/

PamGene is a Dutch biotech company that supports scientists and companies in finding biomarker solutions using an innovative, multiplex kinome profiling technology. PamGene has recently registered two CE-IVD blood tests to help physicians improving the outcome of cancer patients treated with immune checkpoint blockers. Through the support of oncologists and their patients the IOpener® blood test can now be successfully initiated in the diagnostic market for melanoma and lung cancer.

For more information, visit: https://pamgene.com/

Pangea Laboratory is a Southern Californian-based CAP-accredited and CLIA-certified facility, focusing on urinary epigenetic oncology diagnostics, with bench-strength in Next Generation Sequencing for research and industrial applications.

For more information, visit: https://pangealab.com/

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Prolight wants to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Its launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

For more information, visit: https://prolightdx.com/en/

Sciomics offers robust immune-based proteomics for biomarker development. Explore its CRO services or partner with the company to advance AKI diagnostics to the market.

For more information, visit: https://www.sciomics.de/